Shots:
- Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of Rs. 39/tablet
- Cipla receives the DCGI approval for Ciplenza (favipiravir- 200mg) targeting the unmet medical needs for COVID-19 treatment options in the country through restricted emergency use. The company will launch Ciplenza in the first week of August priced at Rs 68/ tablet
- Moreover- Brinton gets DCGI approval drug favipiravir under the brand name Faviton (Rs 59/ tablet) for the treatment of COVID-19 patients. Faviton is a generic version of Avigan of Fujifilm Toyama- a subsidiary of Fujifilm Corporation
Cipla- Jenburkt- Brinton Ref: Cipla- Jenburkt- Brinton | Image: Pharmashots
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
